NCT05208398 is a Phase 3 clinical trial of Apixaban in Left Ventricular Thrombus, sponsored by Saud Al Babtain Cardiac Center.

Who is sponsoring NCT05208398?

NCT05208398 is sponsored by Saud Al Babtain Cardiac Center.

What drugs are being tested in NCT05208398?

Interventions in NCT05208398: Apixaban, Warfarin.

What condition does NCT05208398 study?

NCT05208398 studies Left Ventricular Thrombus.

Is NCT05208398 still recruiting?

NCT05208398 is currently completed. Last updated 26 January 2022.

Last reviewed 2022-01-26 · How we verify

NCT05208398

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Apixaban in Patients With Left Ventricular Thrombus

Completed Phase 3 Last updated 26 January 2022

What this trial tests

Phase 3 trial testing Apixaban in Left Ventricular Thrombus in 50 participants. Completed in 30 September 2021.

Timeline

18 February 2018

Primary endpoint
30 September 2021

30 September 2021

Quick facts

Lead sponsor	Saud Al Babtain Cardiac Center
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	50
Start date	18 February 2018
Primary completion	30 September 2021
Estimated completion	30 September 2021
Sites	1 location across Saudi Arabia

Drugs / interventions tested

Apixaban (apixaban) — full drug profile →
Warfarin (warfarin) — full drug profile →

Conditions studied

Left Ventricular Thrombus — all drugs for Left Ventricular Thrombus →

Sponsor

Saud Al Babtain Cardiac Center

Who can join

Adults 18 to 80, any sex, with Left Ventricular Thrombus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Open label randomized controlled clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in treating left ventricular thrombus in patients with acute or recent myocardial infarction (MI).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Apixaban in Patients With Post-Myocardial Infarction Left Ventricular Thrombus: A Randomized Clinical Trial.
Youssef AA, Alrefae MA, Khalil HH, Abdullah HI, et al · · 2023 · cited 24× · PMID 37013071 · DOI 10.1016/j.cjco.2022.12.003

Verify or expand the search:

Other trials of Apixaban

Trials testing the same drug.

NCT06953726 — Comparing the Safety and Efficacy of Apixaban and Rivaroxaban · Phase 4 · not yet recruiting
NCT07493304 — Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Canc · Phase 3 · not yet recruiting
NCT07521332 — Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis · Phase 4 · recruiting
NCT07160686 — Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment · Phase 3 · not yet recruiting
NCT07404345 — Low-Dose Apixaban Added to Standard Heparin Lock Versus Heparin Lock Alone to Prevent Tunneled Hemodialysis Catheters Dy · Phase 4 · not yet recruiting

Other recruiting trials for Left Ventricular Thrombus

Currently open trials in the same condition.

NCT06515730 — Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction · Phase 4 · recruiting
NCT06742567 — Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction · Phase 3 · recruiting

Other Saud Al Babtain Cardiac Center trials

Trials by the same sponsor.

NCT05210972 — Coronary Artery Disease Severity in Newly Diagnosed Dysglycemia · completed
NCT04427046 — Acute Myocardial Infarction in Native Versus Non-native Young Population in Saudi Arabia · completed
NCT05208424 — New Diabetes Mellitus and Pre-Diabetes With First-time Diagnosed Coronary Artery Disease · completed
NCT04303390 — 24 Vs 48 Hours of Cefazolin or Cefuroxime as Prophylaxis · Phase 4 · completed
NCT04572061 — Emergency Coronary Artery Bypass Graft in Acute Myocardial Infarction · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05208398 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Saud Al Babtain Cardiac Center
Last refreshed: 26 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05208398.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing